Dystonia Therapeutic Assessment Pipeline Review H1 2015 Market Research Report Available at RnRMarketResearch.com

Share Article

RnRMarketResearch.com adds “Dystonia – Pipeline Review, H1 2015” to its store. The report provides an overview of the Dystonia’s therapeutic pipeline.

Dystonia Therapeutic Assessment Pipeline

Dystonia Therapeutic Assessment Pipeline

The report “Dystonia – Pipeline Review, H1 2015” provides comprehensive information on the therapeutic development for Dystonia. Dystonia is characterized by persistent or intermittent muscle contractions causing abnormal, often repetitive, movements, postures, or both. Dystonia affects men, women, and children of all ages and backgrounds. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report on H1 2015 pipeline review of Dystonia with 19 market data tables and 13 figures, spread across 48 pages is available at http://www.rnrmarketresearch.com/dystonia-pipeline-review-h1-2015-market-report.html .

Companies discussed in this Dystonia – Pipeline Review, H1 2015 report include Addex Therapeutics Ltd, Advicenne Pharma, EpiVax, Inc., Ipsen S.A., Medy-Tox Inc.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Drug Profiles mentioned in this report are abobotulinumtoxin A, abobotulinumtoxin A next generation, ADV-6979, dipraglurant ER, dipraglurant IR, onabotulinumtoxin A, onabotulinumtoxin A.

Featured News & Press Releases cover by this report includes: Jan 19, 2015: Addex and Dystonia Medical Research Foundation Announce Partnership to Explore the Therapeutic use of Dipraglurant in the Treatment of Dystonia; Apr 04, 2014: Medytox Meditoxin(Neuronox) registered in 27 countries worldwide; Feb 05, 2014: Ipsen announces clinical results of Dysport Next Generation and its intent to file the first ready-to-use liquid toxin A in Europe and ROW; Sep 04, 2013: Chronic treatment with Addex Dipraglurant Rescues Impairment of Long-Term Synaptic Plasticity in a Validated Preclinical Model of Primary Generalized Torsion Dystonia 1; Apr 22, 2013: Addex Obtains European Composition Of Matter Patent Covering Dipraglurant And Other mGlu5 Negative Allosteric Modulators; Apr 18, 2013: Addex's Dipraglurant Normalizes Striatal Cholinergic Dysfunction In Validated Preclinical Model Of Primary Generalized Torsion Dystonia 1; Jan 29, 2013: Addex Therapeutics's Dipraglurant Reduces Motor Abnormalities In Preclinical Model Of Dystonia; Feb 26, 2007: Epivax Funded To Advance Research On A New, Improved "Botox".

Order a purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=386034 . (This is a premium report priced at US$2000 for a single user License.)
List of Tables
Number of Products under Development for Dystonia, H1 2015 7
Number of Products under Development for Dystonia - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Comparative Analysis by Late Stage Development, H1 2015 10
Comparative Analysis by Clinical Stage Development, H1 2015 11
Comparative Analysis by Early Stage Development, H1 2015 12
Products under Development by Companies, H1 2015 13
Dystonia - Pipeline by Addex Therapeutics Ltd, H1 2015 14
Dystonia - Pipeline by Advicenne Pharma, H1 2015 15
Dystonia - Pipeline by EpiVax, Inc., H1 2015 16
Dystonia - Pipeline by Ipsen S.A., H1 2015 17
Dystonia - Pipeline by Medy-Tox Inc., H1 2015 18
Assessment by Monotherapy Products, H1 2015 19
Number of Products by Stage and Target, H1 2015 21
Number of Products by Stage and Mechanism of Action, H1 2015 23
Number of Products by Stage and Route of Administration, H1 2015 25
Number of Products by Stage and Molecule Type, H1 2015 27
Dystonia Therapeutics - Recent Pipeline Updates, H1 2015 36
Dystonia - Dormant Projects, H1 2015 40

List of Figures
Number of Products under Development for Dystonia, H1 2015 7
Number of Products under Development for Dystonia - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Comparative Analysis by Clinical Stage Development, H1 2015 11
Assessment by Monotherapy Products, H1 2015 19
Number of Products by Top 10 Targets, H1 2015 20
Number of Products by Stage and Top 10 Targets, H1 2015 21
Number of Products by Top 10 Mechanism of Actions, H1 2015 22
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 23
Number of Products by Top 10 Routes of Administration, H1 2015 24
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 25
Number of Products by Top 10 Molecule Types, H1 2015 26
Number of Products by Stage and Top 10 Molecule Types, H1 2015 27

Explore more reports on Neurology therapeutics at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/neurology-therapeutics .

About Us:
RnRMarketResearch.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Ritesh Tiwari
@chinamrreport
Follow >
Market Reports China
Like >
Follow us on
Visit website